0.00%
0.02%
78.59%
243.76%
475.98%
635.79%
1343.78%
AI Spotlight on ALPN
Company Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.
Alpine Immune Sciences, Inc.was incorporated in 2007 and is headquartered in Seattle, Washington.
Market Data
| Last Price | 64.97 |
| Change Percentage | 0.02% |
| Open | 64.98 |
| Previous Close | 64.96 |
| Market Cap ( Millions) | 4457 |
| Volume | 4288333 |
| Year High | 65 |
| Year Low | 8.33 |
| M A 50 | 52.49 |
| M A 200 | 26.27 |
Financial Ratios
| FCF Yield | -1.82% |
| Dividend Yield | 0.00% |
| ROE | -14.86% |
| Debt / Equity | 2.90% |
| Net Debt / EBIDTA | 51.44% |
| Price To Book | 12.5 |
| Price Earnings Ratio | -112.94 |
| Price To FCF | -55.05 |
| Price To sales | 78.85 |
| EV / EBITDA | -97.62 |
News
- May -02 - Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
- Apr -26 - ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
- Apr -17 - SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Encore Wire Corporation - WIRE
- Apr -15 - Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
- Apr -13 - Could This Stock Be the Next Biotech Buyout?
- Apr -12 - Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
- Apr -11 - 2 Biotech Stocks Driving the Nasdaq Today
- Apr -11 - Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal
- Apr -11 - Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
- Apr -11 - The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
- Apr -11 - Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
- Apr -11 - Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
- Apr -11 - Alpine Immune Sciences soars on $4.9bn Vertex takeover
- Apr -11 - Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
- Apr -11 - Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
- Apr -11 - Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
- Apr -11 - ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
- Apr -10 - Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
- Apr -10 - Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
- Apr -10 - Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Protein-based Immunotherapies
Expected Growth : 11.3 %
What the company do ?
Protein-based Immunotherapies from Alpine Immune Sciences, Inc. are novel treatments that utilize engineered proteins to stimulate the immune system to fight cancer and autoimmune diseases.
Why we expect these perspectives ?
Alpine Immune Sciences' 11.3% growth in Protein-based Immunotherapies is driven by increasing adoption in cancer treatment, rising demand for personalized medicine, and advancements in gene editing technologies like CRISPR. Additionally, strategic partnerships and collaborations are expanding the company's pipeline and accelerating clinical trials, further fueling growth.
Alpine Immune Sciences, Inc. Products
| Product Range | What is it ? |
|---|---|
| ALPN-101 | A dual-acting fusion protein designed to block CD28 and CD80/86, which are key targets for autoimmune disease treatment. |
| ALPN-202 | A variant of the CD28 receptor that selectively binds to CD80/86, blocking the co-stimulatory signal and reducing T cell activation. |
| Transmembrane Immunomodulatory Proteins (TIPs) | A novel class of immunomodulatory proteins that can be engineered to target specific immune cells and modulate their activity. |
| Variant Ig Domain (vIgD) | A novel class of immunomodulatory proteins that can be engineered to target specific immune cells and modulate their activity. |
Alpine Immune Sciences, Inc.'s Porter Forces
Threat Of Substitutes
Alpine Immune Sciences, Inc. has a low threat of substitutes due to its unique and patented technology in the development of novel protein-based immunotherapies.
Bargaining Power Of Customers
Alpine Immune Sciences, Inc. has a medium bargaining power of customers due to the presence of a few large pharmaceutical companies that can influence the market.
Bargaining Power Of Suppliers
Alpine Immune Sciences, Inc. has a low bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and equipment.
Threat Of New Entrants
Alpine Immune Sciences, Inc. has a high threat of new entrants due to the growing interest in immunotherapy and the increasing number of biotech startups.
Intensity Of Rivalry
Alpine Immune Sciences, Inc. operates in a moderately competitive industry with a few established players, leading to a medium intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.93% |
| Debt Cost | 3.95% |
| Equity Weight | 97.07% |
| Equity Cost | 8.79% |
| WACC | 8.65% |
| Leverage | 3.02% |
Alpine Immune Sciences, Inc. : Quality Control
Alpine Immune Sciences, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CORT | Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a … |
| NVAX | Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a … |
| ACLX | Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which … |
| INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
| ADMA | ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Corcept Therapeutics
A-Score
1-Year Total Return ->
🥈
Novavax
A-Score
1-Year Total Return ->
🥉
Alpine Immune Sciences
A-Score
1-Year Total Return ->
4
ADMA Biologics
A-Score
1-Year Total Return ->
5
Insmed
A-Score
1-Year Total Return ->
6
